-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 14, LENZ Therapeutics announced that it has signed an exclusive agreement with Keixing Pharma to develop and commercialize LNZ100 (acetylcridine) and LNZ101 (acetylcridine + brimonidine) for the treatment of presbyopia in Greater China.
Under the terms of the agreement, LENZ will receive an upfront payment of $15 million and may receive additional payments of up to $95 million, subject to development, approval and commercialization milestones and franchises based on future net sales usage fee
Note: The original text has been deleted